vs
雅培（ABT）与GENMAB A/S（GMAB）财务数据对比。点击上方公司名可切换其他公司
雅培的季度营收约是GENMAB A/S的12.4倍（$11.5B vs $925.0M）。GENMAB A/S净利率更高（36.3% vs 15.5%，领先20.8%）。GENMAB A/S同比增速更快（18.7% vs 4.4%）。雅培自由现金流更多（$2.6B vs $327.0M）
雅培是总部位于美国伊利诺伊州雅培园的跨国医疗健康企业，业务覆盖美国境外市场药品销售、诊断产品、营养产品及医疗器械等板块，在全球医疗健康领域拥有较高的行业知名度与广泛的市场覆盖。
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
ABT vs GMAB — 直观对比
营收规模更大
ABT
是对方的12.4倍
$925.0M
营收增速更快
GMAB
高出14.3%
4.4%
净利率更高
GMAB
高出20.8%
15.5%
自由现金流更多
ABT
多$2.3B
$327.0M
损益表 — Q4 2025 vs Q2 2025
| 指标 | | |
|---|---|---|
| 营收 | $11.5B | $925.0M |
| 净利润 | $1.8B | $336.0M |
| 毛利率 | 57.0% | 93.8% |
| 营业利润率 | 19.6% | 38.9% |
| 净利率 | 15.5% | 36.3% |
| 营收同比 | 4.4% | 18.7% |
| 净利润同比 | -80.8% | 65.5% |
| 每股收益（稀释后） | $1.01 | $5.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABTGMAB
| Q4 25 | $11.5B | — | ||
| Q3 25 | $11.4B | — | ||
| Q2 25 | $11.1B | $925.0M | ||
| Q1 25 | $10.4B | — | ||
| Q4 24 | $11.0B | — | ||
| Q3 24 | $10.6B | — | ||
| Q2 24 | $10.4B | $779.0M | ||
| Q1 24 | $10.0B | — |
净利润ABTGMAB
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.8B | $336.0M | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $9.2B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.3B | $203.0M | ||
| Q1 24 | $1.2B | — |
毛利率ABTGMAB
| Q4 25 | 57.0% | — | ||
| Q3 25 | 55.4% | — | ||
| Q2 25 | 56.4% | 93.8% | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 55.0% | — | ||
| Q3 24 | 55.8% | — | ||
| Q2 24 | 55.6% | 96.4% | ||
| Q1 24 | 55.2% | — |
营业利润率ABTGMAB
| Q4 25 | 19.6% | — | ||
| Q3 25 | 18.1% | — | ||
| Q2 25 | 18.4% | 38.9% | ||
| Q1 25 | 16.3% | — | ||
| Q4 24 | 17.4% | — | ||
| Q3 24 | 17.5% | — | ||
| Q2 24 | 16.1% | 30.3% | ||
| Q1 24 | 13.9% | — |
净利率ABTGMAB
| Q4 25 | 15.5% | — | ||
| Q3 25 | 14.5% | — | ||
| Q2 25 | 16.0% | 36.3% | ||
| Q1 25 | 12.8% | — | ||
| Q4 24 | 84.1% | — | ||
| Q3 24 | 15.5% | — | ||
| Q2 24 | 12.5% | 26.1% | ||
| Q1 24 | 12.3% | — |
每股收益（稀释后）ABTGMAB
| Q4 25 | $1.01 | — | ||
| Q3 25 | $0.94 | — | ||
| Q2 25 | $1.01 | $5.42 | ||
| Q1 25 | $0.76 | — | ||
| Q4 24 | $5.26 | — | ||
| Q3 24 | $0.94 | — | ||
| Q2 24 | $0.74 | $3.13 | ||
| Q1 24 | $0.70 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.9B | $1.3B |
| 总债务越低越好 | $12.9B | — |
| 股东权益账面价值 | $52.1B | $5.3B |
| 总资产 | $86.7B | $6.5B |
| 负债/权益比越低杠杆越低 | 0.25× | — |
8季度趋势，按日历期对齐
现金及短期投资ABTGMAB
| Q4 25 | $8.9B | — | ||
| Q3 25 | $7.7B | — | ||
| Q2 25 | $7.3B | $1.3B | ||
| Q1 25 | $6.8B | — | ||
| Q4 24 | $8.0B | — | ||
| Q3 24 | $7.8B | — | ||
| Q2 24 | $7.2B | $622.0M | ||
| Q1 24 | $6.7B | — |
总债务ABTGMAB
| Q4 25 | $12.9B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $14.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ABTGMAB
| Q4 25 | $52.1B | — | ||
| Q3 25 | $51.0B | — | ||
| Q2 25 | $50.6B | $5.3B | ||
| Q1 25 | $48.8B | — | ||
| Q4 24 | $47.7B | — | ||
| Q3 24 | $39.8B | — | ||
| Q2 24 | $39.3B | $4.4B | ||
| Q1 24 | $38.8B | — |
总资产ABTGMAB
| Q4 25 | $86.7B | — | ||
| Q3 25 | $84.2B | — | ||
| Q2 25 | $84.0B | $6.5B | ||
| Q1 25 | $81.4B | — | ||
| Q4 24 | $81.4B | — | ||
| Q3 24 | $74.4B | — | ||
| Q2 24 | $73.0B | $5.6B | ||
| Q1 24 | $72.5B | — |
负债/权益比ABTGMAB
| Q4 25 | 0.25× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.30× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $349.0M |
| 自由现金流经营现金流 - 资本支出 | $2.6B | $327.0M |
| 自由现金流率自由现金流/营收 | 22.9% | 35.4% |
| 资本支出强度资本支出/营收 | 6.0% | 2.4% |
| 现金转化率经营现金流/净利润 | 1.87× | 1.04× |
| 过去12个月自由现金流最近4个季度 | $7.4B | — |
8季度趋势，按日历期对齐
经营现金流ABTGMAB
| Q4 25 | $3.3B | — | ||
| Q3 25 | $2.8B | — | ||
| Q2 25 | $2.0B | $349.0M | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $2.9B | — | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $2.0B | $438.0M | ||
| Q1 24 | $1.0B | — |
自由现金流ABTGMAB
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $1.5B | $327.0M | ||
| Q1 25 | $933.0M | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $1.4B | $430.0M | ||
| Q1 24 | $627.0M | — |
自由现金流率ABTGMAB
| Q4 25 | 22.9% | — | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 13.9% | 35.4% | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 20.2% | — | ||
| Q2 24 | 13.8% | 55.2% | ||
| Q1 24 | 6.3% | — |
资本支出强度ABTGMAB
| Q4 25 | 6.0% | — | ||
| Q3 25 | 4.4% | — | ||
| Q2 25 | 4.5% | 2.4% | ||
| Q1 25 | 4.7% | — | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 5.1% | 1.0% | ||
| Q1 24 | 4.0% | — |
现金转化率ABTGMAB
| Q4 25 | 1.87× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.15× | 1.04× | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 1.64× | — | ||
| Q2 24 | 1.51× | 2.16× | ||
| Q1 24 | 0.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABT
暂无分部数据
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
